Dr. Janeway is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Dana Farber Cancer Institute
44 Binney Street
Boston, MA 02115Phone+1 617-632-4994
Education & Training
- Boston Children’s Hospital/Boston Medical CenterFellowship, Pediatric Hematology/Oncology, 2004 - 2007
- Boston Children’s Hospital/Boston Medical CenterResidency, Pediatrics, 2000 - 2004
- Harvard Medical SchoolClass of 2000
Certifications & Licensure
- ME State Medical License Current
- MA State Medical License 2003 - 2026
- RI State Medical License 2022 - 2026
- VT State Medical License 2022 - 2026
- CT State Medical License 2022 - 2025
- NH State Medical License 2024 - 2024
- American Board of Pediatrics Pediatric Hematology-Oncology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
Clinical Trials
- iCAT for Recurrent/Refractory/HR Solid Tumors Start of enrollment: 2012 Aug 01
- The iCat2, GAIN (Genomic Assessment Informs Novel Therapy) Consortium Study Start of enrollment: 2015 Oct 01
- Olaparib With Ceralasertib in Recurrent Osteosarcoma Start of enrollment: 2020 Nov 24
Publications & Presentations
PubMed
- Rare germline structural variants increase risk for pediatric solid tumors.Riaz Gillani, Ryan L Collins, Jett Crowdis, Amanda Garza, Jill K Jones
Science. 2025-01-03 - Optimizing Ewing Sarcoma and Osteosarcoma Biopsy Acquisition: A Children's Oncology Group Bone Tumor Committee Consensus Statement.Matthew S Dietz, Alyaa Al-Ibraheemi, Jessica L Davis, C Matthew Hawkins, Brian T Craig
Journal of the National Comprehensive Cancer Network. 2024-12-27 - 1 citationsLenvatinib Plus Ifosfamide and Etoposide in Children and Young Adults With Relapsed Osteosarcoma: A Phase 2 Randomized Clinical Trial.Nathalie Gaspar, Giun-Yi Hung, Sandra J Strauss, Quentin Campbell-Hewson, Filemon S Dela Cruz
JAMA Oncology. 2024-12-01
Journal Articles
- Institutional Implementation of Clinical Tumor Profiling on an Unselected Cancer PopulationKhanh Do, Lauren L Ritterhouse, William C Hahn, Geoffrey I Shapiro, Barrett J Rollins, Neal I Lindeman, Alanna Church, Geoffrey R Oxnard, Bruce E Johnson, Frank C Kuo,..., The Journal of Clinical Investigation
- Integrated Genetic and Pharmacologic Interrogation of Rare CancersAndrew L Hong, Katherine A Janeway, Brian D Crompton, Kimberly Stegmaier, Levi A Garraway, Alanna J Church, Stuart L Schreiber, William C Hahn, Nature
Lectures
- Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory or High-Risk Leukemias: A Report from the LEAP ConsortiumClinically Relevant Abstract2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Refining the Genomic Landscape of Pediatric Cancers2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Other
- Chemotherapy and radiation therapy in the management of osteosarcomaJaneway KA, Goorin AM, Maki R
http://www.uptodate.com/contents/chemotherapy-and-radiation-therapy-in-the-management-of-osteosarcom
UpToDate, Wolters Kluwer Health - 2012-12-06
Press Mentions
- Peptomyc Announces the Beginning of a Phase 2 Clinical Trial of OMO-103 in Advanced OsteosarcomaJanuary 16th, 2025
- Genomic ‘Fingerprinting’ Yields Better Treatments for Pediatric Solid CancersJune 24th, 2022
- Study Shows That Genomic Tumor Profiling of Pediatric Tumors Can Enhance Clinical CareJune 23rd, 2022
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: